Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NRIX |
---|---|---|
09:32 ET | 10191 | 17 |
09:34 ET | 1459 | 16.97 |
09:36 ET | 1493 | 16.68 |
09:38 ET | 434 | 16.695 |
09:41 ET | 14237 | 16.55 |
09:43 ET | 357 | 16.55 |
09:45 ET | 3137 | 16.6 |
09:48 ET | 2500 | 16.55 |
09:50 ET | 10532 | 16.45 |
09:52 ET | 5637 | 16.44 |
09:54 ET | 4538 | 16.46 |
09:56 ET | 3260 | 16.47 |
09:57 ET | 2553 | 16.62 |
09:59 ET | 5187 | 16.52 |
10:01 ET | 6302 | 16.39 |
10:03 ET | 1284 | 16.45 |
10:06 ET | 8059 | 16.545 |
10:12 ET | 2842 | 16.675 |
10:14 ET | 1413 | 16.8 |
10:15 ET | 2600 | 16.8 |
10:17 ET | 300 | 16.84 |
10:19 ET | 1436 | 16.86 |
10:21 ET | 300 | 16.91 |
10:24 ET | 3207 | 16.81 |
10:26 ET | 2200 | 16.785 |
10:28 ET | 2658 | 16.785 |
10:30 ET | 6221 | 16.79 |
10:32 ET | 5190 | 16.77 |
10:33 ET | 1844 | 16.8 |
10:35 ET | 2039 | 16.76 |
10:37 ET | 1978 | 16.72 |
10:39 ET | 2887 | 16.74 |
10:42 ET | 1929 | 16.7 |
10:44 ET | 5779 | 16.745 |
10:46 ET | 476 | 16.74 |
10:48 ET | 3257 | 16.74 |
10:50 ET | 322 | 16.75 |
10:51 ET | 4275 | 16.75 |
10:53 ET | 891 | 16.755 |
10:55 ET | 1545 | 16.79 |
10:57 ET | 902 | 16.76 |
11:00 ET | 1475 | 16.78 |
11:02 ET | 2713 | 16.75 |
11:04 ET | 2814 | 16.8 |
11:06 ET | 6355 | 16.72 |
11:08 ET | 2102 | 16.7 |
11:09 ET | 5206 | 16.75 |
11:11 ET | 700 | 16.72 |
11:13 ET | 5379 | 16.725 |
11:15 ET | 300 | 16.72 |
11:18 ET | 5602 | 16.75 |
11:20 ET | 1800 | 16.73 |
11:22 ET | 2969 | 16.785 |
11:24 ET | 200 | 16.78 |
11:26 ET | 2614 | 16.795 |
11:27 ET | 1881 | 16.87 |
11:29 ET | 5453 | 16.86 |
11:31 ET | 1305 | 16.79 |
11:33 ET | 2792 | 16.88 |
11:36 ET | 3518 | 16.85 |
11:38 ET | 200 | 16.86 |
11:40 ET | 400 | 16.91 |
11:42 ET | 2296 | 16.945 |
11:44 ET | 1288 | 16.97 |
11:45 ET | 400 | 16.98 |
11:49 ET | 5346 | 16.91 |
11:51 ET | 1936 | 16.88 |
11:54 ET | 1741 | 16.93 |
11:56 ET | 1270 | 16.9 |
11:58 ET | 2548 | 16.91 |
12:00 ET | 2711 | 16.895 |
12:02 ET | 500 | 16.87 |
12:03 ET | 2513 | 16.9 |
12:05 ET | 4718 | 16.94 |
12:07 ET | 300 | 16.95 |
12:09 ET | 1900 | 16.92 |
12:12 ET | 300 | 16.91 |
12:14 ET | 4073 | 16.99 |
12:16 ET | 1365 | 16.91 |
12:18 ET | 900 | 16.91 |
12:20 ET | 1929 | 16.95 |
12:21 ET | 447 | 16.96 |
12:23 ET | 1495 | 16.93 |
12:25 ET | 1418 | 16.94 |
12:27 ET | 100 | 16.94 |
12:30 ET | 749 | 16.985 |
12:32 ET | 1315 | 16.97 |
12:34 ET | 200 | 16.97 |
12:36 ET | 2361 | 16.97 |
12:38 ET | 718 | 16.94 |
12:39 ET | 711 | 16.84 |
12:41 ET | 1111 | 16.83 |
12:43 ET | 200 | 16.78 |
12:45 ET | 404 | 16.81 |
12:48 ET | 1674 | 16.77 |
12:50 ET | 1086 | 16.78 |
12:52 ET | 837 | 16.82 |
12:54 ET | 907 | 16.9 |
12:56 ET | 900 | 16.86 |
12:59 ET | 1853 | 16.88 |
01:01 ET | 1839 | 16.925 |
01:03 ET | 500 | 16.92 |
01:06 ET | 300 | 16.97 |
01:08 ET | 1598 | 16.95 |
01:10 ET | 852 | 16.93 |
01:12 ET | 2248 | 16.97 |
01:14 ET | 1739 | 16.93 |
01:15 ET | 1300 | 16.9 |
01:17 ET | 2108 | 16.91 |
01:19 ET | 1568 | 16.88 |
01:21 ET | 648 | 16.885 |
01:24 ET | 1331 | 16.87 |
01:26 ET | 700 | 16.87 |
01:28 ET | 1500 | 16.9 |
01:30 ET | 2800 | 16.89 |
01:32 ET | 700 | 16.88 |
01:33 ET | 600 | 16.82 |
01:35 ET | 2893 | 16.785 |
01:37 ET | 1004 | 16.8 |
01:39 ET | 1226 | 16.83 |
01:42 ET | 100 | 16.8623 |
01:44 ET | 642 | 16.87 |
01:46 ET | 965 | 16.87 |
01:48 ET | 200 | 16.885 |
01:50 ET | 1100 | 16.87 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Nurix Therapeutics Inc | 908.5M | -6.4x | --- |
Arcutis Biotherapeutics Inc | 872.9M | -2.8x | --- |
Zymeworks Inc | 634.2M | -5.4x | --- |
Gyre Therapeutics Inc | 959.4M | -5.8x | --- |
CureVac NV | 1.0B | -3.2x | --- |
SAGE Therapeutics Inc | 656.0M | -1.3x | --- |
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $908.5M |
---|---|
Revenue (TTM) | $80.9M |
Shares Outstanding | 59.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.17 |
EPS | $-2.65 |
Book Value | $4.12 |
P/E Ratio | -6.4x |
Price/Sales (TTM) | 11.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -194.51% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.